In last trading session, Cleveland BioLabs, Inc. (NASDAQ:CBLI) saw 4,813,015 shares changing hands with its beta currently measuring 0.97. Company’s recent per share price level of $2.635 trading at $0.74 or 43.02% at recent trade assigns it a market valuation of $31.78 Million. That current price of CBLI’s stock is at a discount of -89.75% from its 52-week high price of $5 and is indicating a premium of 81.02% from its 52-week low price of $0.5. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 400.4 Million shares which gives us an average trading volume of 282.49 Million if we extend that period to 3-months.

For Cleveland BioLabs, Inc. (CBLI), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 0. Splitting up the data highlights that, out of 1 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas none see the stock as a Buy. None analyst(s) advised it as an Underweight.

Cleveland BioLabs, Inc. (NASDAQ:CBLI) trade information

Upright in the green today for gaining 39.24%, in the last five days CBLI remained trading in the green while hitting it’s week-highest on Friday, Jun 26 when the stock touched $2.38 price level, adding 10.5% to its value on the day. Cleveland BioLabs, Inc.’s shares saw a change of 253.82% in year-to-date performance and have moved 27.54% in past 5-day. Cleveland BioLabs, Inc. (NASDAQ:CBLI) showed a performance of 3.9% in past 30-days. Number of shares sold short was 10.98 Million shares which calculate 0.04 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $40 to the stock, which implies a rise of 1418.03% to its current value. Analysts have been projecting $40 as a low price target for the stock while placing it at a high target of $40. It follows that stock’s current price would jump +1418.03% in reaching the projected high whereas dropping to the targeted low would mean a loss of 1418.03% for stock’s current value.

Cleveland BioLabs, Inc. (CBLI) estimates and forecasts

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -19% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 26.7% while estimates for its earnings growth in next 5 years are of 0%